ConductScience.org, home

Paper7591963

Cytotoxic activity of CD4+ T cells against autologous tumor cells.

Konomi Y and 4 others. Jpn J Cancer Res, 1995. Cited by 12 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Cytotoxic activity of CD4+ T cells against autologous tumor cells. Papers, record 7591963. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7591963

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cytotoxic activity of CD4+ T cells against autologous tumor cells.
PubMed
Journal
Jpn J Cancer Res
PubMed
Year
1995
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
0.31
iCite
Revised in PubMed
2019-05-12
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Konomi YY
2Sekine TT
3Takayama TT
4Fuji MM
5Tanaka TT

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CD4-Positive T-LymphocytesMajor topic
Immunotherapy, AdoptiveMajor topic
NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
CD4-CD8 Ratio
CD8-Positive T-Lymphocytes
Chromium
Chromium Radioisotopes
Colorimetry
Cytotoxicity, Immunologic
Female
Gentian Violet
Humans
Lymphocytes, Tumor-Infiltrating
Male
Middle Aged

Source PubMed

Download CSV of topics

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13259261Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.J Clin Oncol1988https://conductscience.org/library/papers/3259261PubMed
2215560Cytolytic and cytostatic activity on tumor cells of circulating human monocytes.Int J Cancer1979https://conductscience.org/library/papers/215560PubMed
32795092Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.J Biol Response Mod1989https://conductscience.org/library/papers/2795092PubMed
43262710Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.J Exp Med1988https://conductscience.org/library/papers/3262710PubMed
51593137The use of [35S]methionine as a target cell label in long term cytotoxic assays.J Immunol Methods1992https://conductscience.org/library/papers/1593137PubMed
66862692Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions.Int J Cancer1983https://conductscience.org/library/papers/6862692PubMed
72437237Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection.J Exp Med1987https://conductscience.org/library/papers/2437237PubMed
83158702Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes.J Immunol1985https://conductscience.org/library/papers/3158702PubMed
91979348Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks.J Biol Response Mod1990https://conductscience.org/library/papers/1979348PubMed
107507026Rapid separation of CD4+ and CD19+ lymphocyte populations from human peripheral blood by a magnetic activated cell sorter (MACS).Cytometry1993https://conductscience.org/library/papers/7507026PubMed
111371532A new method for detachment of Dynabeads from positively selected B lymphocytes.J Immunol Methods1992https://conductscience.org/library/papers/1371532PubMed
128513449Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8513449PubMed
131970108Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma.Lancet1990https://conductscience.org/library/papers/1970108PubMed
148218952A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients.Biomed Pharmacother1993https://conductscience.org/library/papers/8218952PubMed
158348560Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8348560PubMed
166198422Cloned LYT-2+ cytolytic T lymphocytes destroy allogeneic tissue in vivo.J Exp Med1984https://conductscience.org/library/papers/6198422PubMed
176602860Clonal analysis of cytotoxic T cell response against human melanoma.J Exp Med1983https://conductscience.org/library/papers/6602860PubMed
188392912Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8392912PubMed
193264384Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.N Engl J Med1988https://conductscience.org/library/papers/3264384PubMed
203100623Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.J Immunol1987https://conductscience.org/library/papers/3100623PubMed

See all 33 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn Papers
31285957Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma.Am J Cancer Res2019https://conductscience.org/library/papers/31285957

Source PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7591963

GET https://conductscience.org/api/papers/v1/7591963/references?page=2